~ Un-Common Sense In An Irrational World: We Challenge the Conventional WisdomTM ~
TRETHERA ANNOUNCES COMPLETION OF PHASE 1 TRE-515 DOSE -ESCALATION TRIAL
Trethera recently announced a significant milestone in its clinical program — the completion of the Phase 1 dose-escalation trial of its investigational therapy, TRE-515, a novel drug candidate with broad potential to treat cancers and autoimmune diseases including prostate cancer, ALS, lupus, Crohn’s disease, multiple sclerosis, and more. TRE-515 has already received millions in NIH grant funding, Orphan Drug Designation for two rare diseases, and FDA Fast Track Designation for prostate cancer.
Highlights:
- Safety: TRE-515 was well tolerated at all dose levels (up to 1,440 mg daily) with no dose-limiting toxicities.
- Preliminary Clinical Activity: Early signals of disease control were observed in a subset of heavily pretreated patients with advanced solid tumors.
- Target Engagement: Biomarker data confirmed on-target inhibition of deoxycytidine kinase (dCK), supporting TRE-515’s intended mechanism of action.
These findings support continued evaluation of TRE-515 across oncology and autoimmune indications.
Read the full press release: Phase 1 Trial of TRE-515 Shows Safety, Target Engagement | Trethera
For investor inquiries, please contact Trethera’s Investor Relations at ir@trethera.com.